Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196676 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01196676: Completed Phase 1 study, sponsored by AstraZeneca.
NCT01196676 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196676, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a single ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD4451.
Interventions
- DRUG Placebo
- DRUG AZD4451
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
What the finished NCT01196676 record still lists
NCT01196676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01196676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01196676 about?
NCT01196676 is a clinical study titled "Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451". This is a single ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD4451.
What is the current status of trial NCT01196676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2010-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01196676?
The interventions under investigation include: Placebo (DRUG), AZD4451 (DRUG).
Who is sponsoring clinical trial NCT01196676?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01196676's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia